美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Electra Therapeutics INC

13.25

-1.7500-11.67%

盘后：13.520.2700+2.04%19:59 EDT

成交量：512.43万

成交额：7,457.47万

市值：8.10亿

市盈率：- -

高：15.50

开：15.00

低：13.25

收：15.00

52周最高：15.50

52周最低：13.25

股本：6,110.03万

流通股本：2,166.67万

量比：- -

换手率：23.65%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Electra Therapeutics INC

交易所：

NASDAQ

成立时间：

2018

员工人数：

- -

公司地址：

230 E Grand Avenue,Suite S-100,South San Francisco,California,United States

官网：

http://electra-therapeutics.com

邮编：

94080

电话：

传真：

- -

简介：

Electra Therapeutics, Inc.成立于2018年，是一家处于临床后期阶段的生物制药公司，致力于开发用于治疗免疫介导疾病和癌症的新型精准药物。该公司的研发策略靶向信号调节蛋白（SIRP），这是一类细胞表面受体，其表达仅限于特定的免疫细胞群，并在激活后表达上调。SIRP能够选择性地清除致病细胞，同时保留正常的免疫功能。该公司的主要候选产品是ipsoprubart，一种新型泛SIRP单克隆抗体，旨在选择性地清除病理性髓系细胞和T细胞。此外，该公司还在推进ELA822的研发，ELA822是一种新型SIRPg特异性单克隆抗体，旨在选择性地清除活化的T细胞，具有治疗慢性T细胞介导的免疫和炎症性疾病的潜在应用价值。

董事

名称

职位

Nancy Stagliano

Chairman of the Board and Director

Quehuong Dong

Chief Executive Officer and Director and President

Beth Seidenberg

Director

Carl L. Gordon

Director

Matthew Fust

Director

Thomas Geninatti

Director

股东

名称

职位

Quehuong Dong

Chief Executive Officer and Director and President

Chris Clark

Chief Financial Officer

Gary S. Koe

Chief Technical Officer

Graham Parry

Chief Scientific Officer

Kim Hien Dao

Chief Medical Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/ETRA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ETRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ETRA\",,,,,undefined,":{"symbol":"ETRA","market":"US","secType":"STK","nameCN":"Electra Therapeutics INC","latestPrice":13.25,"timestamp":1789761600000,"preClose":15,"halted":0,"volume":5124319,"hourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.25,"latestTime":"19:59 EDT","volume":17079,"amount":234585.3427,"timestamp":1789775990519,"change":0.27,"changeRate":0.020377,"amplitude":0.037736},"delay":0,"changeRate":-0.11666666666666667,"floatShares":21666667,"shares":61100300,"eps":0,"marketStatus":"已收盘","change":-1.75,"latestTime":"09-18 16:00:00 EDT","open":15,"high":15.5,"low":13.25,"amount":74574706.341624,"amplitude":0.15,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":5,"adr":0,"listingDate":1789704000000,"exchange":"NASDAQ","adjPreClose":15,"postHourTrading":{"tag":"盘后","latestPrice":13.52,"preClose":13.25,"latestTime":"19:59 EDT","volume":17079,"amount":234585.3427,"timestamp":1789775990519,"change":0.27,"changeRate":0.020377,"amplitude":0.037736},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ETRA\",,,,,undefined,":{"symbol":"ETRA","floatShares":21666667,"roa":"--","roe":"--","lyrEps":0,"shares":61100300,"dividePrice":0,"high":15.5,"amplitude":0.15,"preClose":15,"low":13.25,"week52Low":13.25,"pbRate":"--","week52High":15.5,"institutionHeld":0,"latestPrice":13.25,"eps":0,"divideRate":0,"volume":5124319,"delay":0,"ttmEps":0,"open":15,"prevYearClose":15,"prevWeekClose":15,"prevMonthClose":15,"prevQuarterClose":15,"fiveDayClose":15,"twentyDayClose":15,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ETRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ETRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ETRA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1771786528,"yearFounded":2018,"address":"230 E Grand Avenue,Suite S-100,South San Francisco,California,United States","zipCode":"94080","officePhone":"(888) 743-2290"},"stockCompanyDetail":{"websiteUrl":"http://electra-therapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Electra Therapeutics, Inc.成立于2018年，是一家处于临床后期阶段的生物制药公司，致力于开发用于治疗免疫介导疾病和癌症的新型精准药物。该公司的研发策略靶向信号调节蛋白（SIRP），这是一类细胞表面受体，其表达仅限于特定的免疫细胞群，并在激活后表达上调。SIRP能够选择性地清除致病细胞，同时保留正常的免疫功能。该公司的主要候选产品是ipsoprubart，一种新型泛SIRP单克隆抗体，旨在选择性地清除病理性髓系细胞和T细胞。此外，该公司还在推进ELA822的研发，ELA822是一种新型SIRPg特异性单克隆抗体，旨在选择性地清除活化的T细胞，具有治疗慢性T细胞介导的免疫和炎症性疾病的潜在应用价值。","exchange":"NASDAQ","name":"Electra Therapeutics INC","nameEN":"ELECTRA THERAPEUTICS INC"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ETRA\",market:\"US\",,,undefined,":{"directors":[{"name":"Nancy Stagliano","position":"Chairman of the Board and Director"},{"name":"Quehuong Dong","position":"Chief Executive Officer and Director and President"},{"name":"Beth Seidenberg","position":"Director"},{"name":"Carl L. Gordon","position":"Director"},{"name":"Matthew Fust","position":"Director"},{"name":"Thomas Geninatti","position":"Director"}],"executives":[{"name":"Quehuong Dong","position":"Chief Executive Officer and Director and President"},{"name":"Chris Clark","position":"Chief Financial Officer"},{"name":"Gary S. Koe","position":"Chief Technical Officer"},{"name":"Graham Parry","position":"Chief Scientific Officer"},{"name":"Kim Hien Dao","position":"Chief Medical Officer"}]}}}